Anderson E L, Gramling P K, Vestal P R, Farrar W E
Antimicrob Agents Chemother. 1975 Sep;8(3):300-4. doi: 10.1128/AAC.8.3.300.
To explore more effective therapy for Pseudomonas aeruginosa, 264 recent clinical isolates were tested by agar dilution using gentamicin and tobramycin alone and combined with carbenicillin to seek synergistic effects. Synergism was defined as a fourfold or greater decrease in the minimal inhibitory concentration of each drug in a pair. At a concentration of 3.12 mug/ml, gentamicin inhibited 73% of the strains and tobramycin inhibited 98%. The gentamicin-carbenicillin combination was synergistically active against 57% of the strains, and tobramycin-carbenicillin was active against 46%. The effect did not correlate with either susceptibility or resistance to gentamicin or tobramycin alone. The data suggest that tobramycin or tobramycin plus carbenicillin may provide alternate therapy where susceptibility to gentamicin or synergism between gentamicin and carbenicillin cannot be demonstrated; however, the degree of susceptibility to either aminoglycoside antibiotic alone cannot be used to predict a synergistic effect.
为探索对铜绿假单胞菌更有效的治疗方法,采用琼脂稀释法,使用庆大霉素和妥布霉素单独及与羧苄西林联合,对264株近期临床分离株进行检测,以寻找协同效应。协同作用定义为一对药物中每种药物的最低抑菌浓度降低四倍或更多。在浓度为3.12微克/毫升时,庆大霉素抑制了73%的菌株,妥布霉素抑制了98%。庆大霉素-羧苄西林组合对57%的菌株有协同活性,妥布霉素-羧苄西林对46%的菌株有活性。该效应与单独对庆大霉素或妥布霉素的敏感性或耐药性均无关联。数据表明,在无法证明对庆大霉素敏感或庆大霉素与羧苄西林之间存在协同作用的情况下,妥布霉素或妥布霉素加羧苄西林可能提供替代治疗;然而,单独对任何一种氨基糖苷类抗生素的敏感程度都不能用于预测协同效应。